Hepatic Disease Treatment Market Size and Share Outlook - Forecast Trends and Growth Analysis Report (2025-2034)
Description
The hepatic disease treatment market was valued at USD 24.78 Billion in 2024, driven by the rising prevalence of liver diseases across the 8 major markets. It is further expected to grow at a CAGR of about 6.20% in the forecast period of 2025-2034 to reach a value of around USD 45.22 Billion by 2034.
Hepatic Disease Treatment Market Overview
Hepatic disease refers to various disorders that impair or prevent the liver from functioning properly. Yellowing of the skin or eyes (jaundice), abdominal pain, or abnormal liver function test results may indicate liver illness. Common liver ailments include cancer, hepatitis, autoimmune diseases, and genetic problems.
The rise in the prevalence of liver diseases, such as non-alcoholic fatty liver disease (NAFLD), liver cirrhosis, hepatitis, alcoholic hepatitis, and liver cancer worldwide is largely due to an unhealthy lifestyle and excessive alcohol consumption. The high burden of liver disease is propelling the demand for the hepatic disease treatment market. One of the primary factors augmenting the market growth is the increasing geriatric population, which is susceptible to a variety of chronic diseases, including liver disease. Moreover, the quick acceptance of antiviral medications, which are safe and efficient in suppressing the hepatitis B virus and lowering the risk of developing cirrhosis and hepatocellular carcinoma, is favorably influencing the market growth.
Further, increasing research and development activities, significant growth in the healthcare industry, and implementation of various government initiatives in order to promote public health are creating a positive outlook for the hepatic disease treatment market value. For instance, the Indian government announced the integration of non-alcoholic fatty liver disease (NAFLD) with the National Program for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS). This program is mainly focused on early diagnosis and management of NAFLD, along with building healthcare infrastructure for the prevention, diagnosis, and treatment of NAFLD. Additionally, the development of novel therapeutics and advancements in diagnostic techniques are some of the factors aiding the market expansion.
Hepatic Disease Treatment Market Growth Drivers
Increasing Prevalence of Liver Diseases to Affect the Market Landscape Significantly
Recent studies reveal that liver disease is responsible for 2 million deaths every year and accounts for 4% of all deaths worldwide (1 in every 25 deaths). It is reported that roughly two-thirds of all liver-related deaths occur in males. Liver cancer also poses a significant health challenge, causing 600,000 to 900,000 deaths annually, primarily as a result of cirrhosis and hepatocellular carcinoma . According to the American Cancer Society, the year 2024 will witness the diagnosis of around 41,630 individuals with primary liver cancer and intrahepatic bile duct cancer in the United States. Further, it is also estimated that 29,840 individuals will die from these cancers , indicating the need for effective medications to combat this liver disease. Thus, the rising burden of liver diseases is set to bolster the growth and innovation in the market.
Hepatic Disease Treatment Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Advancements in Diagnostic Technologies
One of the major market trends is the rising improvements in diagnostic technologies such as imaging techniques (MRI, CT scans) and biomarker-based tests. These advancements help in the early and accurate diagnosis of liver diseases._x000D_
Increased Investment in R&D
Increased funding and grants for research and development of hepatic disease treatments by the government and healthcare organizations is a major market trend. This investment is expected to accelerate the discovery and commercialization of new and effective therapies, which is anticipated to boost the hepatic disease treatment market value._x000D_
Growing Regulatory Support
The market benefits from the presence of a favorable regulatory environment, with regulatory bodies offering orphan drug designations and incentives for novel therapies that are designed to treat rare liver diseases. In addition, the implementation of fast-track and accelerated approval processes is anticipated to support market expansion in the forecast period._x000D_
Heightened Public Awareness
The market is witnessing heightened public awareness regarding liver diseases and their treatments which is prompting more individuals to seek medical attention. This trend is supported by rising public health campaigns and education programs aimed at highlighting the importance of early intervention and adherence to treatment protocols.
Hepatic Disease Treatment Market Segmentation
Hepatic Disease Treatment Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Treatment Type
The Antiviral Drugs Segment Based on Treatment Type is Anticipated to Witness Substantial Growth
Based on the treatment type, the market is segmented into antiviral drugs, monoclonal antibodies, immunosuppressant drugs, vaccines, corticosteroid drugs, targeted therapy, and others. The antiviral drugs segment holds a high market value which can be attributed to the high prevalence of viral hepatitis such as hepatitis B and C which can result in chronic liver diseases, cirrhosis, and liver cancer. The chronic nature of these hepatic diseases drives the need for long-term antiviral treatment.
Hepatic Disease Treatment Market Analysis by Region
The United States represents a major market for hepatic disease treatment owing to the high prevalence of liver diseases including hepatitis B and C. According to the Centers for Disease Control and Prevention, roughly 800,000 to 1.4 million Americans have chronic hepatitis B virus (HBV) infection, and hepatitis B is the underlying cause of 2,000 to 4,000 fatalities in the United States each year. The increasing number of cases of such liver diseases propels the demand for effective treatments and therapeutics in the region. India is also projected to have substantial market growth in the forecast period owing to improvements in healthcare infrastructure, rising spending on healthcare services, and increased government funds and grants for research and development of hepatic disease treatments.
Leading Players in the Hepatic Disease Treatment Market
The key features of the market report comprise the patent analysis, clinical trial analysis, grant analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
AbbVie Inc.
American pharmaceutical company AbbVie is a major market player and invests heavily in R&D to develop innovative therapies for hepatic diseases. The company is known for its combination therapies to treat chronic hepatitis C virus (HCV) infection such as its FDA-approved combination drug MAVYRET (glecaprevir/pibrentasvir).
Merck & Co., Inc.
United States-based Merck & Co., focuses on developing novel treatments for liver diseases, including both antivirals and vaccines. The company is also involved in health initiatives aimed at eliminating hepatitis.
F. Hoffmann-La Roche Ltd
Swiss multinational holding healthcare company Roche is engaged in advancing its pipeline of hepatic disease treatments. Its drug Pegasys (peginterferon alfa-2a) is often used in combination with other antiviral medications to treat chronic hepatitis B and C infections.
Eli Lilly and Company
Headquartered in Indiana (United States), pharmaceutical giant Eli Lilly and Company is one of the key players in the market. It is focused on developing treatments that target liver cancer and fibrosis._x000D_
Key Questions Answered in the Hepatic Disease Treatment Market Report
Hepatic Disease Treatment Market Overview
Hepatic disease refers to various disorders that impair or prevent the liver from functioning properly. Yellowing of the skin or eyes (jaundice), abdominal pain, or abnormal liver function test results may indicate liver illness. Common liver ailments include cancer, hepatitis, autoimmune diseases, and genetic problems.
The rise in the prevalence of liver diseases, such as non-alcoholic fatty liver disease (NAFLD), liver cirrhosis, hepatitis, alcoholic hepatitis, and liver cancer worldwide is largely due to an unhealthy lifestyle and excessive alcohol consumption. The high burden of liver disease is propelling the demand for the hepatic disease treatment market. One of the primary factors augmenting the market growth is the increasing geriatric population, which is susceptible to a variety of chronic diseases, including liver disease. Moreover, the quick acceptance of antiviral medications, which are safe and efficient in suppressing the hepatitis B virus and lowering the risk of developing cirrhosis and hepatocellular carcinoma, is favorably influencing the market growth.
Further, increasing research and development activities, significant growth in the healthcare industry, and implementation of various government initiatives in order to promote public health are creating a positive outlook for the hepatic disease treatment market value. For instance, the Indian government announced the integration of non-alcoholic fatty liver disease (NAFLD) with the National Program for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS). This program is mainly focused on early diagnosis and management of NAFLD, along with building healthcare infrastructure for the prevention, diagnosis, and treatment of NAFLD. Additionally, the development of novel therapeutics and advancements in diagnostic techniques are some of the factors aiding the market expansion.
Hepatic Disease Treatment Market Growth Drivers
Increasing Prevalence of Liver Diseases to Affect the Market Landscape Significantly
Recent studies reveal that liver disease is responsible for 2 million deaths every year and accounts for 4% of all deaths worldwide (1 in every 25 deaths). It is reported that roughly two-thirds of all liver-related deaths occur in males. Liver cancer also poses a significant health challenge, causing 600,000 to 900,000 deaths annually, primarily as a result of cirrhosis and hepatocellular carcinoma . According to the American Cancer Society, the year 2024 will witness the diagnosis of around 41,630 individuals with primary liver cancer and intrahepatic bile duct cancer in the United States. Further, it is also estimated that 29,840 individuals will die from these cancers , indicating the need for effective medications to combat this liver disease. Thus, the rising burden of liver diseases is set to bolster the growth and innovation in the market.
Hepatic Disease Treatment Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Advancements in Diagnostic Technologies
One of the major market trends is the rising improvements in diagnostic technologies such as imaging techniques (MRI, CT scans) and biomarker-based tests. These advancements help in the early and accurate diagnosis of liver diseases._x000D_
Increased Investment in R&D
Increased funding and grants for research and development of hepatic disease treatments by the government and healthcare organizations is a major market trend. This investment is expected to accelerate the discovery and commercialization of new and effective therapies, which is anticipated to boost the hepatic disease treatment market value._x000D_
Growing Regulatory Support
The market benefits from the presence of a favorable regulatory environment, with regulatory bodies offering orphan drug designations and incentives for novel therapies that are designed to treat rare liver diseases. In addition, the implementation of fast-track and accelerated approval processes is anticipated to support market expansion in the forecast period._x000D_
Heightened Public Awareness
The market is witnessing heightened public awareness regarding liver diseases and their treatments which is prompting more individuals to seek medical attention. This trend is supported by rising public health campaigns and education programs aimed at highlighting the importance of early intervention and adherence to treatment protocols.
Hepatic Disease Treatment Market Segmentation
Hepatic Disease Treatment Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Treatment Type
- Antiviral Drugs
- Monoclonal Antibodies
- Immunosuppressants Drugs
- Vaccines
- Corticosteroids Drugs
- Targeted Therapy
- Others
- Hepatitis
- Non-Alcoholic Fatty Liver Disease (NAFLD)
- Hepatic Cancer
- Other
- Parenteral
- Oral
- Others
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
The Antiviral Drugs Segment Based on Treatment Type is Anticipated to Witness Substantial Growth
Based on the treatment type, the market is segmented into antiviral drugs, monoclonal antibodies, immunosuppressant drugs, vaccines, corticosteroid drugs, targeted therapy, and others. The antiviral drugs segment holds a high market value which can be attributed to the high prevalence of viral hepatitis such as hepatitis B and C which can result in chronic liver diseases, cirrhosis, and liver cancer. The chronic nature of these hepatic diseases drives the need for long-term antiviral treatment.
Hepatic Disease Treatment Market Analysis by Region
The United States represents a major market for hepatic disease treatment owing to the high prevalence of liver diseases including hepatitis B and C. According to the Centers for Disease Control and Prevention, roughly 800,000 to 1.4 million Americans have chronic hepatitis B virus (HBV) infection, and hepatitis B is the underlying cause of 2,000 to 4,000 fatalities in the United States each year. The increasing number of cases of such liver diseases propels the demand for effective treatments and therapeutics in the region. India is also projected to have substantial market growth in the forecast period owing to improvements in healthcare infrastructure, rising spending on healthcare services, and increased government funds and grants for research and development of hepatic disease treatments.
Leading Players in the Hepatic Disease Treatment Market
The key features of the market report comprise the patent analysis, clinical trial analysis, grant analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
AbbVie Inc.
American pharmaceutical company AbbVie is a major market player and invests heavily in R&D to develop innovative therapies for hepatic diseases. The company is known for its combination therapies to treat chronic hepatitis C virus (HCV) infection such as its FDA-approved combination drug MAVYRET (glecaprevir/pibrentasvir).
Merck & Co., Inc.
United States-based Merck & Co., focuses on developing novel treatments for liver diseases, including both antivirals and vaccines. The company is also involved in health initiatives aimed at eliminating hepatitis.
F. Hoffmann-La Roche Ltd
Swiss multinational holding healthcare company Roche is engaged in advancing its pipeline of hepatic disease treatments. Its drug Pegasys (peginterferon alfa-2a) is often used in combination with other antiviral medications to treat chronic hepatitis B and C infections.
Eli Lilly and Company
Headquartered in Indiana (United States), pharmaceutical giant Eli Lilly and Company is one of the key players in the market. It is focused on developing treatments that target liver cancer and fibrosis._x000D_
Key Questions Answered in the Hepatic Disease Treatment Market Report
- What was the hepatic disease treatment market value in 2024?
- What is the hepatic disease treatment market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is market segmentation based on the treatment type?
- What is the market breakup based on the disease type?
- What is the market breakup by route of administration?
- What are the major factors aiding the hepatic disease treatment market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- How do the prevalence and incidence of hepatic diseases affect the market landscape?
- What are the major hepatic disease treatment market trends?
- How does the rise in the geriatric population impact the market size?
- Which treatment type will dominate the market share?
- Which disease type is expected to have a high market value in the coming years?
- Which route of administration will experience the highest demand in the market segment?
- Who are the key players involved in the hepatic disease treatment market?
- What is the patent landscape of the market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Hepatic Disease Treatment Market Overview: 8 Major Market
- 3.1 Hepatic Disease Treatment Market Historical Value (2018-2024)
- 3.2 Hepatic Disease Treatment Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Hepatic Disease Treatment Market: Disease Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Therapy Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Therapy Success Rate
- 7 Hepatic Disease Treatment Market Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview (2018-2034)
- 7.1.1 Prevalence, by Country
- 7.1.1.1 U.S.
- 7.1.1.2 U.K.
- 7.1.1.3 EU4
- 7.1.1.4 India
- 7.1.1.5 Japan
- 7.1.2 Mortality by Country
- 7.1.2.1 U.S.
- 7.1.2.2 U.K.
- 7.1.2.3 EU4
- 7.1.2.4 India
- 7.1.2.5 Japan
- 7.1.3 Treatment Seeking Rate by Country
- 7.1.3.1 U.S.
- 7.1.3.2 U.K.
- 7.1.3.3 EU4
- 7.1.3.4 India
- 7.1.3.5 Japan
- 8 Hepatic Disease Treatment Market Landscape: 8 Major Market*
- 8.1 Hepatic Disease Treatment Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Hepatic Disease Treatment Market: Product Landscape
- 8.2.1 Analysis by Treatment Type
- 8.2.2 Analysis by Disease Type
- 8.2.3 Analysis by Route of Administration
- 9 Hepatic Disease Treatment Market Therapy Challenges and Unmet Needs
- 9.1 Therapy Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Therapy
- 11 Hepatic Disease Treatment: Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Hepatic Disease Treatment Market Segmentation: 8 Major Markets
- 12.1 Hepatic Disease Treatment Market by Treatment Type
- 12.1.1 Market Overview
- 12.1.2 Antiviral Drugs
- 12.1.3 Monoclonal Antibodies
- 12.1.4 Immunosuppressants Drugs
- 12.1.5 Vaccines
- 12.1.6 Corticosteroids Drugs
- 12.1.7 Targeted Therapy
- 12.1.8 Others
- 12.2 Hepatic Disease Treatment Market by Disease Type
- 12.2.1 Market Overview
- 12.2.2 Hepatitis
- 12.2.3 Non-Alcoholic Fatty Liver Disease (NAFLD)
- 12.2.4 Hepatic Cancer
- 12.2.5 Other
- 12.3 Hepatic Disease Treatment Market by Route of Administration
- 12.3.1 Market Overview
- 12.3.2 Parenteral
- 12.3.3 Oral
- 12.3.4 Others
- 12.4 Hepatic Disease Treatment Market by Region
- 12.4.1 Market Overview
- 12.4.2 United States
- 12.4.3 EU-4 and the United Kingdom
- 12.4.3.1 Germany
- 12.4.3.2 France
- 12.4.3.3 Italy
- 12.4.3.4 Spain
- 12.4.3.5 United Kingdom
- 12.4.4 Japan
- 12.4.5 India
- 13 United States Hepatic Disease Treatment Market (218-2034)
- 13.1 United States Hepatic Disease Treatment Market Historical Value (2018-2024)
- 13.2 United States Hepatic Disease Treatment Market Forecast Value (2025-2034)
- 13.3 United States Hepatic Disease Treatment Market by Treatment Type
- 13.3.1 Market Overview
- 13.3.2 Antiviral Drugs
- 13.3.3 Monoclonal Antibodies
- 13.3.4 Immunosuppressants Drugs
- 13.3.5 Vaccines
- 13.3.6 Corticosteroids Drugs
- 13.3.7 Targeted Therapy
- 13.3.8 Others
- 13.4 United States Hepatic Disease Treatment Market by Disease Type
- 13.4.1 Market Overview
- 13.4.2 Hepatitis
- 13.4.3 Non-Alcoholic Fatty Liver Disease (NAFLD)
- 13.4.4 Hepatic Cancer
- 13.4.5 Other
- 13.5 United States Hepatic Disease Treatment Market by Route of Administration
- 13.5.1 Market Overview
- 13.5.2 Parenteral
- 13.5.3 Oral
- 13.5.4 Others
- 14 EU-4 and United Kingdom Hepatic Disease Treatment Market (218-2034)
- 14.1 EU-4 and United Kingdom Hepatic Disease Treatment Market Historical Value (2018-2024)
- 14.2 EU-4 and United Kingdom Hepatic Disease Treatment Market Forecast Value (2025-2034)
- 14.3 EU-4 and United Kingdom Hepatic Disease Treatment Market by Treatment Type
- 14.3.1 Market Overview
- 14.3.2 Antiviral Drugs
- 14.3.3 Monoclonal Antibodies
- 14.3.4 Immunosuppressants Drugs
- 14.3.5 Vaccines
- 14.3.6 Corticosteroids Drugs
- 14.3.7 Targeted Therapy
- 14.3.8 Others
- 14.4 EU-4 and United Kingdom Hepatic Disease Treatment Market by Disease Type
- 14.4.1 Market Overview
- 14.4.2 Hepatitis
- 14.4.3 Non-Alcoholic Fatty Liver Disease (NAFLD)
- 14.4.4 Hepatic Cancer
- 14.4.5 Other
- 14.5 EU-4 and United Kingdom Hepatic Disease Treatment Market by Route of Administration
- 14.5.1 Market Overview
- 14.5.2 Parenteral
- 14.5.3 Oral
- 14.5.4 Others
- 15 Japan Hepatic Disease Treatment Market
- 15.1 Japan Hepatic Disease Treatment Market Historical Value (2018-2024)
- 15.2 Japan Hepatic Disease Treatment Market Forecast Value (2025-2034)
- 15.3 Japan Hepatic Disease Treatment Market by Treatment Type
- 15.3.1 Market Overview
- 15.3.2 Antiviral Drugs
- 15.3.3 Monoclonal Antibodies
- 15.3.4 Immunosuppressants Drugs
- 15.3.5 Vaccines
- 15.3.6 Corticosteroids Drugs
- 15.3.7 Targeted Therapy
- 15.3.8 Others
- 15.4 Japan Hepatic Disease Treatment Market by Disease Type
- 15.4.1 Market Overview
- 15.4.2 Hepatitis
- 15.4.3 Non-Alcoholic Fatty Liver Disease (NAFLD)
- 15.4.4 Hepatic Cancer
- 15.4.5 Other
- 15.5 Japan Hepatic Disease Treatment Market by Route of Administration
- 15.5.1 Market Overview
- 15.5.2 Parenteral
- 15.5.3 Oral
- 15.5.4 Others
- 16 India Hepatic Disease Treatment Market
- 16.1 India Hepatic Disease Treatment Market (2018-2034) Historical Value (2018-2024)
- 16.2 India Hepatic Disease Treatment Market (2018-2034) Forecast Value (2025-2034)
- 16.3 India Hepatic Disease Treatment Market by Treatment Type
- 16.3.1 Market Overview
- 16.3.2 Antiviral Drugs
- 16.3.3 Monoclonal Antibodies
- 16.3.4 Immunosuppressants Drugs
- 16.3.5 Vaccines
- 16.3.6 Corticosteroids Drugs
- 16.3.7 Targeted Therapy
- 16.3.8 Others
- 16.4 India Hepatic Disease Treatment Market by Disease Type
- 16.4.1 Market Overview
- 16.4.2 Hepatitis
- 16.4.3 Non-Alcoholic Fatty Liver Disease (NAFLD)
- 16.4.4 Hepatic Cancer
- 16.4.5 Other
- 16.5 India Hepatic Disease Treatment Market by Route of Administration
- 16.5.1 Market Overview
- 16.5.2 Parenteral
- 16.5.3 Oral
- 16.5.4 Others
- 17 Regulatory Framework
- 17.1 Regulatory Overview
- 17.2 US FDA
- 17.3 EU EMA
- 17.4 INDIA CDSCO
- 17.5 JAPAN PMDA
- 17.6 Others
- 18 Patent Analysis
- 18.1 Analysis by Type of Patent
- 18.2 Analysis by Publication Year
- 18.3 Analysis by Issuing Authority
- 18.4 Analysis by Patent Age
- 18.5 Analysis by CPC Analysis
- 18.6 Analysis by Patent Valuation
- 18.7 Analysis by Key Players
- 19 Clinical Trial Analysis
- 19.1 Analysis by Trial Registration Year
- 19.2 Analysis by Trial Status
- 19.3 Analysis by Trial Phase
- 19.4 Analysis by Therapeutic Area
- 19.5 Analysis by Geography
- 20 Grant Analysis
- 20.1 Analysis by Year
- 20.2 Analysis by Amount Awarded
- 20.3 Analysis by Issuing Authority
- 20.4 Analysis by Grant Product
- 20.5 Analysis by Funding Institute
- 20.6 Analysis by Departments
- 20.7 Analysis by Recipient Organization
- 21 Funding and Investment Analysis
- 21.1 Analysis by Funding Instances
- 21.2 Analysis by Type of Funding
- 21.3 Analysis by Funding Amount
- 21.4 Analysis by Leading Players
- 21.5 Analysis by Leading Investor
- 21.6 Analysis by Geography
- 22 Strategic Initiatives
- 22.1 Analysis by Partnership Instances
- 22.2 Analysis by Type of Partnership
- 22.3 Analysis by Leading Players
- 22.4 Analysis by Geography
- 23 Supplier Landscape
- 23.1 Market Share by Top 5 Companies
- 23.2 AbbVie Inc.
- 23.2.1 Financial Analysis
- 23.2.2 Product Portfolio
- 23.2.3 Demographic Reach and Achievements
- 23.2.4 Company News and Development
- 23.2.5 Certifications
- 23.3 Merck & Co., Inc.
- 23.3.1 Financial Analysis
- 23.3.2 Product Portfolio
- 23.3.3 Demographic Reach and Achievements
- 23.3.4 Company News and Development
- 23.3.5 Certifications
- 23.4 F. Hoffmann-La Roche Ltd
- 23.4.1 Financial Analysis
- 23.4.2 Product Portfolio
- 23.4.3 Demographic Reach and Achievements
- 23.4.4 Company News and Development
- 23.4.5 Certifications
- 23.5 Eli Lilly and Company
- 23.5.1 Financial Analysis
- 23.5.2 Product Portfolio
- 23.5.3 Demographic Reach and Achievements
- 23.5.4 Company News and Development
- 23.5.5 Certifications
- 23.6 Bristol-Myers Squibb Company
- 23.6.1 Financial Analysis
- 23.6.2 Product Portfolio
- 23.6.3 Demographic Reach and Achievements
- 23.6.4 Company News and Development
- 23.6.5 Certifications
- 23.7 Gilead Sciences, Inc.
- 23.7.1 Financial Analysis
- 23.7.2 Product Portfolio
- 23.7.3 Demographic Reach and Achievements
- 23.7.4 Company News and Development
- 23.7.5 Certifications
- 23.8 Novartis AG
- 23.8.1 Financial Analysis
- 23.8.2 Product Portfolio
- 23.8.3 Demographic Reach and Achievements
- 23.8.4 Company News and Development
- 23.8.5 Certifications
- 23.9 Takeda Pharmaceuticals Company Ltd.
- 23.9.1 Financial Analysis
- 23.9.2 Product Portfolio
- 23.9.3 Demographic Reach and Achievements
- 23.9.4 Company News and Development
- 23.9.5 Certifications
- 23.10 Gilead Science, Inc.
- 23.10.1 Financial Analysis
- 23.10.2 Product Portfolio
- 23.10.3 Demographic Reach and Achievements
- 23.10.4 Company News and Development
- 23.10.5 Certifications
- 23.11 Otsuka Holdings
- 23.11.1 Financial Analysis
- 23.11.2 Product Portfolio
- 23.11.3 Demographic Reach and Achievements
- 23.11.4 Company News and Development
- 23.11.5 Certifications
- 23.12 GSK PLC.
- 23.12.1 Financial Analysis
- 23.12.2 Product Portfolio
- 23.12.3 Demographic Reach and Achievements
- 23.12.4 Company News and Development
- 23.12.5 Certifications
- 24 Hepatic Disease Treatment Market – Distribution Model (Additional Insight)
- 24.1 Overview
- 24.2 Potential Distributors
- 24.3 Key Parameters for Distribution Partner Assessment
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
